Splenomegalie

 
Sonderbericht
Mit freundlicher Unterstützung der Genzyme GmbH, Neu-Isenburg
 

Literatur:

1. Linari S, Castaman G, Clin Cases Min Bone Metab 2015, 12:157–164
2. Mistry PK et al., Mol Genet Metab 2017, 120:8–21
3. Mistry PK et al., Am J Hematol 2007, 82:697–701
4. vom Dahl S et al., Best Pract Res Clin Gastroenterol 2010, 24:619–628
5. Motta I et al., Eur J Haematol 2016, 96:352–359
6. Fachinformation Cerdelga®, Stand 9/2017
7. Mistry PK et al., Long-term results of ENGAGE: a phase 3, randomized, double-blind, placebocontrolled, multi-center study investigating the efficacy and safety of eliglustat in adults with Gaucher disease type 1, 13th Annual WORLD Symposium 2017, Poster
8. Mistry PK et al., Mol Genet Metab 2017, 120 (1–2):97–S98
9. Pastores GM, Biodrugs 2010, 24:41–47
10. Goker-Alpan O, Mol Genet Metab 2011, 104:438–447
11. Fachinformation Cerezyme®
12. Cox TM et al., Blood 2017, 129:2375–2383

PDF zum Download

Weitere Beiträge aus diesem Themenbereich